In addition to vipoglanstat, Gesynta Pharma's advanced pipeline comprises a further mPGES-1 inhibitor, GS-073. This candidate drug is ready to enter clinical development for the treatment of chronic inflammatory pain, an area of significant medical need. Gesynta Pharma has developed complete preclinical safety documentation and a study protocol for the GS-073 project.
GS-073 has demonstrated a highly effective suppressive effect on both inflammation and pain in a recently conducted preclinical disease model of arthritis. The primary objective of the planned phase I study is to study the safety, tolerability, and pharmacokinetic properties of GS-073 in healthy participants as well as its effect on relevant biomarkers. This will provide important knowledge for the planning of the continued clinical program.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
The members of Gesynta Pharma's management team and board of directors have extensive experience from drug development and commercialization.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase 2 for endometriosis, while GS-073 is ready to enter clinical phase 1 for chronic inflammatory pain.